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ABSTRACT
The ﬁght against vascular disease requires functional endothelial cells (ECs) which could be pro-
vided by differentiation of induced Pluripotent Stem Cells (iPS Cells) in great numbers for use in
the clinic. However, the great promise of the generated ECs (iPS-ECs) in therapy is often
restricted due to the challenge in iPS-ECs preserving their phenotype and function. We identi-
ﬁed that Follistatin-Like 3 (FSTL3) is highly expressed in iPS-ECs, and, as such, we sought to clar-
ify its possible role in retaining and improving iPS-ECs function and phenotype, which are
crucial in increasing the cells’ potential as a therapeutic tool. We overexpressed FSTL3 in iPS-ECs
and found that FSTL3 could induce and enhance endothelial features by facilitating b-catenin
nuclear translocation through inhibition of glycogen synthase kinase-3b activity and induction of
Endothelin-1. The angiogenic potential of FSTL3 was also conﬁrmed both in vitro and in vivo.
When iPS-ECs overexpressing FSTL3 were subcutaneously injected in in vivo angiogenic model
or intramuscularly injected in a hind limb ischemia NOD.CB17-Prkdcscid/NcrCrl SCID mice model,
FSTL3 signiﬁcantly induced angiogenesis and blood ﬂow recovery, respectively. This study, for
the ﬁrst time, demonstrates that FSTL3 can greatly enhance the function and maturity of iPS-
ECs. It advances our understanding of iPS-ECs and identiﬁes a novel pathway that can be
applied in cell therapy. These ﬁndings could therefore help improve efﬁciency and generation of
therapeutically relevant numbers of ECs for use in patient-speciﬁc cell-based therapies. In addi-
tion, it can be particularly useful toward the treatment of vascular diseases instigated by EC
dysfunction. STEM CELLS 2018; 00:000–000
SIGNIFICANCE STATEMENT
Endothelial cell (EC) reprograming is a highly promising regenerative strategy to develop novel
therapies to improve vascular function in patients with vascular and ischemic diseases. Under-
standing key factors to facilitate maintenance of EC generation and function is important as we all
move towards cell therapy. The present study has elucidated, for the first time, the remarkable
role of follistatin like 3 in improving the function and neovascularization potential in ECs derived
from induced pluripotent stem cells both in vitro and in vivo, by facilitating b-catenin nuclear
translocation, inhibition of glycogen synthase kinase-3b activity and Endothelin-1 induction.
INTRODUCTION
Vascular diseases are some of the leading causes
of mortality worldwide [1] with compromised
endothelial integrity being at the core of their initi-
ation and progression [2]. Vascular endothelial cells
(ECs) regulate vascular tone and growth, perme-
ability, interaction with platelets and leukocytes,
and maintenance of vascular homeostasis [3]. As a
result, any adverse alterations in endothelial physi-
ology increase the risk for vasodegenerative
pathology and tissue nonperfusion [4]. However,
the restoration of the luminal endothelium is a
long and slow process and there are no efﬁcacious
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REGENERATIVE MEDICINE
process. As a result, the repair and regeneration of functional and
healthy ECs in damaged tissues remains an important research
focus in regenerative medicine [5].
In recent years, efforts toward EC restoration has shifted
focus to stem cell-based approaches that include isolation,
expansion, and subsequent differentiation of endothelial pro-
genitor cells [6] or pluripotent ESCs [7] for use as therapeutic
tools. However, delivery of such cells to repair of damaged vas-
culature has encountered many restrictions, including availabil-
ity of suitable and efﬁcacious cells for therapy [8]. As a result,
the capability to derive ECs [induced pluripotent stem (iPS)-ECs]
from iPS Cells holds great potential for the treatment of vascu-
lar disease [9]. Even though the ﬁeld is now rapidly moving
toward EC generation from iPS Cells for use in cell based thera-
pies, the main limitation of generating and maintaining func-
tional ECs with a stable phenotype still remains.
To uncover the full potential of iPS-ECs and their thera-
peutic efﬁcacy, understanding the complex mechanisms con-
trolling these cells is essential. To start uncovering pivotal
mechanisms involved in iPS-ECs, we found that Follistatin-Like
3 (FSTL3) was highly expressed in these cells. This led us to
hypothesize that FSTL3 may play a crucial role in enhancing
iPS-ECs generation in terms of marker expression as well as
function and angiogenic potential.
Follistatin is a secreted protein that in humans is encoded by the
FST gene [10] and contains three conserved follistatin domains
(FSDs) [11]. It is a glycosylated single-chain protein, originally
observed in ovarian follicular ﬂuid that reduces follicle-stimulating
hormone secretion [12]. Follistatin-like (FSTL) proteins contain a mini-
mum of one FSD and have heterogeneous, but partly characterized,
functions [11]. Like follistatin, FSTL3, also known as FST-related gene
or Follistatin-related protein (FSRP) [13], binds and neutralizes activin,
and other transforming growth factor-beta (TGF-b) ligands [14].
FSTL3 is highly homologous to follistatin, containing two FSDs [15].
Even though FSTL3 is secreted from cells where it is highly expressed,
there is indication that FSTL3 also remains intracellular [15].
Follistatin family members are multifunctional and essen-
tial in tissue restoration and repair and they have been impli-
cated in EC differentiation [16], angiogenesis [17], and
development of vasculature [18]. However, the role of FSTL3
in these processes is largely unknown.
The aim of this study was therefore to elucidate the underly-
ing mechanisms which are governed by FSTL3 in iPS-ECs, and
might drive these cells toward a more stable and functional
stage. Our ﬁndings demonstrate that FSTL3 is regulated by KLF4
during iPS-ECs generation and has a key role in improving func-
tion in iPS-ECs. In particular, FSTL3 enhances the expression of
EC markers by increasing b-catenin protein translocation to the
nucleus through inhibiting glycogen synthase kinase-3b (GSK3b)
activity and induction of Endothelin-1. Importantly, these results
were conﬁrmed in vivo when iPS-ECs overexpressing FSTL3 sig-
niﬁcantly improved angiogenesis and neovascularization and
blood ﬂow recovery in the hind limb ischemic model.
MATERIALS AND METHODS
Cell culture media, serum, and cell culture supplements were
purchased from ATCC, USA, Merck Millipore, USA, LONZA, Swit-
zerland and Thermo Fisher Scientiﬁc, USA. Antibodies against VE-
Cadherin (CD144) (ab33168 and STJ96234), VEGFR (ab9530),
GAPDH (ab8245), OCT-4 (ab19857 and STJ72238), KLF4
(ab72543) eNOS (ab76198), and FSTL3 (STJ112317) were pur-
chased from Abcam, UK or St John’s Laboratory, UK. Antibodies
against vWF (SC-8068) were purchased from Santa Cruz, USA.
KDR (MAB3571), b-actin (MAB8929), recombinant FSTL3
(AF1288-F3), and Proteome Proﬁler Array Human Angiogenesis
Array Kit (ARY007) were purchased from R&D, USA.
Human iPS Cells Differentiation
Four different clones of human iPS Cells were differentiated using
StemPro-34 SFM serum free media (Thermo Fisher Scientiﬁc)
supplemented with BMP4 (Thermo Fisher Scientiﬁc), Activin A
(R&D), ﬁbroblast growth factor (FGF) (Miltenyi Biotec, Germany),
and vascular endothelial growth factor (VEGF) (Thermo Fisher
Scientiﬁc) for 5 days. The differentiated cells were seeded on col-
lagen IV (R&D), while CD144 positive cells were magnetically
sorted on day 6 using MicroBeads Kit (Miltenyi BIotec) and cul-
tured in EGM-2 media (LONZA) (iPS-ECs). FSTL3 was overex-
pressed or knocked down by transfection or lentiviral gene
transfer in iPS-ECs and the cells were harvested 2–3 days later
for further analysis or used for in vivo angiogenesis and hind
limb ischemia assays. Equal cell numbers were used between
control and treated conditions in all experiments in this study.
In Vivo Matrigel Plug Assay. In in vivo angiogenesis assays,
iPS-ECs overexpressing FSTL3 (EX-FSTL3) or control plasmid (EX-
mCherry) were mixed with 50 ll of Matrigel and injected subcu-
taneously into the back or ﬂank of NOD.CB17-Prkdcscid/NcrCrl
severe combined immunodeﬁciency (SCID) mice. Six injections
were conducted for each group. Seven days later, the mice
were sacriﬁced and the plugs were harvested, frozen in liquid
nitrogen, and cryosectioned. Samples were ﬁxed with 4% para-
formaldehyde in phosphate buffered saline (PBS) at 48C over-
night, and then H&E staining was performed. Images were
assessed with Axioplan 2 imaging microscope with Plan-
NEOFLUAR 310, NA 0.3, objective lenses, AxioCam camera, and
Axiovision software (all Carl Zeiss MicroImaging, Inc., Germany).
Experimental Hind Limb Ischemia
The mouse hind limb ischemia model was performed as previ-
ously described [19, 20]. iPS-ECs overexpressing FSTL3 (EX-FSTL3)
or control plasmid (EX-mCherry) were trypsinized and injected
intramuscularly into the adductors of ischemic NOD.CB17-
Prkdcscid/NcrCrl SCID mice. Tissue blood ﬂow of both legs was
sequentially assessed by Laser Doppler imaging (moorLDL2-IR).
Statistical Analysis
Data is expressed as mean6 SEM and analyzed using Graph-
Pad Prism 5 software with a two-tailed Student’s t test for
two groups or pairwise comparisons or analysis of variance
(ANOVA). A value of *, p< .05; **, p< .01; ***, p< .001 was
considered signiﬁcant.
The detailed “Methods and Materials” are given in “Supporting
Information Appendix Experimental Procedures” section.
RESULTS
iPS Cells Differentiation Toward ECs
The model of iPS Cells generation and subsequent EC differ-
entiation have been implemented in follow-up experiments
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where somatic cells were reprogramed to a pluripotent state
according to a standard protocol [21], and as previously
described, giving rise to iPS Cells [22], and Supporting Infor-
mation Figure S1A–S1C. iPS Cells were differentiated to iPS-
ECs by selecting the CD144 positive population, seeding on
collagen IV and culturing in EGM-2 media. iPS-ECs adopted a
distinctive cobble-stone morphology (Fig. 1A). The potential of
the iPS Cells to differentiate toward ECs was conﬁrmed at
both mRNA (Fig. 1B, 1C) and protein level (Fig. 1D, and quan-
tiﬁcation in Fig. 1E), demonstrating that iPS-ECs exhibited
expression of typical early (CD34, KDR) and late EC markers
(CD31, CD144, eNOS, and vWF). Immunoﬂuorescent confocal
microscope images also revealed that iPS-ECs expressed char-
acteristic EC markers such as CD144, KDR, CD31, and vWF
(Fig. 1F). They also exhibited typical EC tube formation on
Matrigel as well as CD144 staining and acetylated-low density
lipoprotein uptake (Fig. 1G). This data conﬁrms the successful
generation of iPS-ECs.
FSTL3 Is Highly Expressed in iPS-ECs
To start elucidating the role of FSTL3 in iPS-ECs, initial real
time experiments using equal numbers of cells, revealed that
FSTL3 was induced during EC differentiation from iPS Cells
both before the selection (at day 6 of EC differentiation) of
CD144 positive cells (pre-iPS-ECs) and after the selection of
CD144 positive cells (iPS-ECs) (Fig. 2A). These results were
also conﬁrmed in protein levels as Western blots data showed
(Fig. 2B, and quantiﬁcation in Fig. 2C) a parallel expression of
FSTL3 and CD144. Interestingly, FSTL3 was also extracellularly
secreted in both pre-iPS-ECs and iPS-ECs as enzyme-linked
immunosorbent assay (ELISA) assays revealed in Figure 2D
when the culture media were assessed. FSTL3 was highly
expressed in iPS-ECs as conﬁrmed by immunoﬂuorescent con-
focal microscopy (Fig. 2E). Furthermore, immunoﬂuorescent
confocal microscopy demonstrated that staining of FSTL3 was
concomitant with the EC-speciﬁc marker CD144 (Fig. 2F), indi-
cating that FSTL3 expression may be an important event in
iPS-ECs. Taken together, these results demonstrate that FSTL3
expression is induced during generation of iPS-ECs and indi-
cate a possible key role of FSTL3 in these cells.
FSTL3 Regulates EC Marker Expression in iPS-ECs
Since expression of FSTL3 was shown to increase in parallel
with EC markers in iPS-ECs, we sought to further clarify the
role of FSTL3 in iPS-ECs. Consequently, we examined whether
manipulating the gene expression of FSTL3 by overexpression
or knockdown experiments or by supplementing the differen-
tiating cells with recombinant FSTL3 protein in the media,
would inﬂuence the EC marker expression. Initially, in order
to assess whether FSTL3 may regulate the EC marker expres-
sion during this process, FSTL3 was overexpressed in iPS-ECs
by transfection or lentiviral gene transfer. Forty eight hours
later, the cells were harvested for further analysis. Since the
plasmids were tagged with the mCherry ﬂuorescent marker,
the transfection/infection efﬁciency could be visualized by
ﬂuorescent microscopy (Fig. 3G). Overexpression of FSTL3 sig-
niﬁcantly increased the expression of EC markers CD144,
eNOS, and KDR (Fig. 3A, 3B, and quantiﬁcation in Fig. 3C) at
both the mRNA and protein levels, respectively. Importantly,
when FSTL3 was silenced by short hairpin RNA (shRNA) in
iPS-ECs, and the cells were harvested 72 hours later, there
was a signiﬁcant downregulation of EC markers in both mRNA
and protein levels, respectively (Fig. 3D, 3E, and quantiﬁcation
in Fig. 3F). The involvement of extracellular FSTL3 (R FSTL3) in
iPS-ECs was evidenced by stimulation using recombinant
FSTL3, which resulted in a signiﬁcant increase in expression of
the EC markers (Fig. 3H). Higher levels of extracellular FSTL3
was also observed in iPS-ECs overexpressing FSTL3, as shown
by ELISA assay (Fig. 3I).
FSTL3 Expression Is Regulated by KLF4
To shed more light on the signaling surrounding FSTL3 activa-
tion in iPS-ECs, the FSTL3 promoter activity was assessed
using Luciferase assays. Overexpression of FSTL3 had no
autoregulatory effects on the FSTL3 promoter in iPS-ECs (Fig.
4A). We [23] and others [24] have previously shown that KLF4
is implicated in EC differentiation from pluripotent stem cells.
In our iPS-ECs system, it was conﬁrmed that KLF4 was
increased during EC differentiation, with a concomitant
decrease of the pluripotent marker OCT4 (Fig. 4B). The next
question was whether FSTL3 may be regulated by KLF4.
Therefore, additional experiments were conducted to clarify
the mechanisms by which FSTL3 could be induced in iPS-ECs
generation. Speciﬁcally, cells were transfected with GFP-
tagged plasmids carrying KLF4 or OCT4 (Fig. 4C), the latter
serving as an additional control, and the levels of FSTL3
expression were observed. FSTL3 levels increased with overex-
pression of KLF4 at both mRNA (Fig. 4E), and protein levels
(Fig. 4F, and quantiﬁcation in Fig. 4G) indicating that KLF4
mediates the induction of FSTL3. Further experiments in iPS-
ECs conﬁrmed that the FSTL3 promoter is regulated by the
KLF4 transcription factor, as Luciferase assays revealed (Fig.
4D). A negative control such as OCT4 was included in these
experiments, showing no effect on FSTL3. In conclusion, our
data demonstrates that FSTL3 is transcriptionally activated by
KLF4 during generation of iPS-ECs.
FSTL3 Regulates EC Marker Expression iPS-ECs by
Facilitating b-Catenin Nuclear Translocation Through
Inhibition of GSK3b Activity
Since FSTL3 was shown to modulate induction of EC markers,
including those particularly localized at cell junctions such as
CD144, we conducted further experiments to elucidate underly-
ing mechanisms in iPS-ECs. There is prior evidence implicating
b-catenin as a key mediator of EC function and being a major
constituent of cell-cell junctions [25]. In dormant cells, b-
catenin is associated with CD144 mainly at the membrane,
maintaining low cytoplasmic levels. When released into the
cytoplasm, b-catenin can either translocate to the nucleus or
incorporate into a cytoplasmic complex, where GSK3b is a key
component, leading to ubiquitination and proteasomal degra-
dation of b-catenin [26]. If GSK3b is blocked or inactivated, the
degradation of b-catenin is attenuated, favoring its nuclear
translocation [26]. When in the nucleus, b-catenin plays a role
in the activation of T-cell factor/lymphoid enhancer factor (LEF)
[27] and it also modulates vascular remodeling [28].
To determine precisely how FSTL3 was involved in
enhancing EC markers, FSTL3 was overexpressed in iPS-ECs,
and the cells were harvested 48 hours later for further anal-
ysis. Overexpression of FSTL3 led to signiﬁcant upregulation
in expression of WNT3, b-catenin, and LEF1, and a signiﬁ-
cant reduction in GSK3b (Fig. 5A). When FSTL3 expression
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was knocked down by shRNA in iPS-ECs, as it has been
described above, this resulted in signiﬁcant suppression of
b-catenin and LEF1 (Fig. 5B). Confocal microscopy of iPS-ECs
showed that FSTL3 was able to enhance b-catenin transloca-
tion to the cell nucleus compared to control (Fig. 5C). Fur-
ther Luciferase assay experiments (Fig. 5D) conﬁrmed the
Figure 1. Induced pluripotent stem cell differentiation toward endothelial cells. Human iPS Cells were differentiated using StemPro
serum free media supplemented with BMP4, Activin A, ﬁbroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) for
5 days. The differentiated cells were seeded on collagen IV, while CD144 positive cells were magnetically sorted on day 6 using MicroBe-
ads Kit (Miltenyi BIotec) and culturing in EGM-2 media (LONZA). (A): Images show morphology of iPS Cells (left panel) and of their dif-
ferentiated EC counterparts (right panel) Scale bar: 50 lm. (B): Real time polymerase chain reaction (PCR) data revealed signiﬁcantly
increased early and (C) late EC marker mRNA expression (Data is means 6SEM [n5 3], *, p< .05; **, p< .01; ***, p< .001). (D): West-
ern blots showing protein expression of the EC-speciﬁc marker CD144 in iPS-ECs and (E) corresponding densitometry. (F): Immunoﬂuo-
rescent confocal images showing that iPS-ECs express typical EC markers, CD144, KDR, CD31, and vWF, also costained with DAPI (40,6-
diamidino-2-phenylindole, dihydrochloride). (G): iPS-ECs stained positive for CD144, were able to uptake LDL and form tubes in vitro.
Scale bar: 50 lm. The data presented are representative or means (6SEM) of three independent experiments. Abbreviations: DAPI,
40,6-diamidino-2-phenylindole; EC, endothelial cell; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; iPS, induced pluripotent stem;
LDL, low density lipoprotein.
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ampliﬁed Top Flash promoter activity by FSTL3, also indicat-
ing increased presence of b-catenin protein levels in the
nucleus. Importantly, the induction of EC markers and LEF1
mediated by FSTL3 was ablated when b-catenin was knocked
down by shRNA (Fig. 5G). The knockdown of b-catenin was
also conﬁrmed in the protein level in Figure 5E, and quanti-
ﬁcation in Figure 5F. In addition, when FSTL3 was overex-
pressed, GSK3b was decreased in the protein level while
phospho-GSK3b, the deactivated form, was increased (Fig.
5H, and quantiﬁcation in Fig. 5I), indicating reduced GSK3b
activity. The angiogenic activity of FSTL3 in regards to b-
catenin involvement was also examined using a human
angiogenesis Proteome Proﬁler array, which identiﬁed
Endothelin-1 being highly induced after FSTL3 overexpression
in iPS-ECs (Fig. 5J). These results clearly demonstrate that
FSTL3 has a critical role in the regulation of EC markers in
iPS-ECs by facilitating b-catenin nuclear translocation through
inhibition of GSK3b activity.
Figure 2. FSTL3 is highly expressed in iPS-ECs. (A): FSTL3 was progressively induced during EC differentiation in iPS-ECs at the mRNA level,
both preselection (pre-iPS-ECs) and postselection with CD144 (iPS-ECs) (Data is means6 SEM [n5 3], *, p< .05). (B): Western Blot showing
FSTL3 protein being expressed in parallel with the EC-speciﬁc marker CD144 and (C) corresponding densitometry. (D): FSTL3 secretion was
progressively induced in cell culture media, as shown by ELISA (Data is means6 SEM [n5 3], *, p< .05). (E): Immunoﬂuorescent images of
FSTL3 in iPS-ECs, Scale bar: 50 mm. (F): Immunoﬂuorescent staining showing that FSTL3 is expressed in parallel with the EC-speciﬁc marker
CD144 in iPS-ECs. Scale bar: 50 mm. The data presented are representative or means (6SEM) of three independent experiments. Abbrevia-
tions: DAPI, 40,6-diamidino-2-phenylindole; ECs, endothelial cells; FSTL3, follistatin-like 3; iPS, induced pluripotent stem.
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FSTL3 Induced Vascular Tube Formation In Vivo
To complement the ﬁndings from our in vitro data and to con-
ﬁrm in vivo relevance, further experiments were conducted to
test whether FSTL3 could induce angiogenesis in vivo. iPS-ECs
were transfected or infected with FSTL3 or control plasmid, and
48 hours later, were mixed with Matrigel and subcutaneously
injected in NOD.CB17-Prkdcscid/NcrCrl SCID mice. Seven days
later, the mice were sacriﬁced, the plugs were harvested and
H&E staining was performed. iPS-ECs overexpressing FSTL3
enhanced the formation of vascular-like tubes in vivo in
Matrigel plug assays as shown by H&E staining in Figure 6A,
and quantiﬁcation of capillary density number in Figure 6B. This
data suggests the notion that FSTL3 improves the function of
iPS-ECs and subsequent angiogenic potential.
FSTL3 Significantly Improved Neovascularization and
Blood Flow Recovery in the Hind Limb Ischemic Model
Further experiments were conducted to test whether FSTL3
could induce angiogenesis in ischemic tissues and improve
blood ﬂow recovery. iPS-ECs overexpressing control mCherry
Figure 3. FSTL3 regulates endothelial cell (EC) marker expression in induced pluripotent stem (iPS)-ECs. iPS-ECs were transfected with the
EX-FSTL3 plasmid carrying the red mCherry ﬂuorophore, or an empty control vector plasmid (EX-mCherry). Forty-eight hours later, FSTL3
overexpression induced (A) mRNA and (B, C) protein expression of EC markers CD144, eNOS, and KDR (Data is means6 SEM [n5 3], **,
p< .01; ***, p< .001). FSTL3 knockdown by short hairpin RNA (shRNA) in iPS-ECs resulted in suppression of EC markers at the (D) mRNA
and (E, F) protein levels when the cells were harvested 72 hours later (Data is means6 SEM [n5 3], ***, p< .001). (G): Fluorescent micro-
scope images of iPS-ECs transfected with EX-FSTL3 plasmid carrying the red mCherry ﬂuorophore, or an empty control vector plasmid (EX-
mCherry). Scale bar: 50 mm. (H): Treatment of the cells with 25–50 ng/ml of recombinant FSTL3 (R FSTL3) increased EC marker expression
such as CD144, eNOS, and KDR compared to phosphate buffered saline (PBS) control (R CTL) (Data is means6 SEM [n5 3], ***, p< .001).
ELISA showing FSTL3 concentration in cell culture media after FSTL3 overexpression compared to control (Data is means6 SEM [n5 3], **,
p< .01). The data presented are representative or means (6SEM) of three independent experiments. Abbreviations: FSTL3, follistatin-like 3;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (I) Enzyme-linked immunosorbent assay (ELISA) showed increased concentration of
FSTL3 in the media after overexpression with EX-FSTL3 plasmid (Data is means 6 SEM [n< 3], **, p< .01
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(EX-mCherry) or FSTL3 (EX-FSTL3) were intramuscularly
injected, along with control PBS (PBS-CTL), after induction of
hind limb ischemia in NOD.CB17-Prkdcscid/NcrCrl SCID mice.
Laser Doppler imaging of blood ﬂow at 14 days postdelivery
of iPS-ECs overexpressing FSTL3 showed improved blood ﬂow
recovery and enhanced neovascularization (Fig. 6C, 6D) in the
ischemic limbs compared to the controls. More speciﬁcally,
engrafted iPS-ECs overexpressing FSTL3 displayed a typical and
well-deﬁned vascular architecture when compared to controls,
as it is shown by confocal immunoﬂuoresent images for the
EC marker CD144 (Fig. 6E). In particular, limbs receiving iPS-
ECs overexpressing FSTL3 displayed signiﬁcantly higher
Figure 4. FSTL3 expression is regulated by KLF4. (A): Luciferase assay of the FSTL3 promoter activity showed no signiﬁcant changes
when FSTL3 was overexpressed compared to empty vector control in iPS-ECs (Data is means6 SEM [n5 3]). (B): During iPS-ECs genera-
tion, KLF4 expression at the mRNA level was increased with a concomitant decrease of the pluripotent marker OCT4 (Data is means6
SEM [n5 3], *, p< .05; **, p< .01). (C): Images of 293-T cells (Scale bar: 100 lm) 48 hours after transfection with GFP-tagged plasmids
carrying the transcription factors OCT4 or KLF4 compared to control (GFP). (D): Luciferase assay in iPS-ECs showed signiﬁcant increase in
the FSTL3 promoter activity after overexpression with KLF4, but not OCT4 (Data is means6 SEM [n5 3], ***, p< .001). (E): mRNA
expression levels 48 hours after transfection with GFP-tagged plasmids carrying the transcription factors OCT4 or KLF4 compared to con-
trol (GFP) (Data is means6 SEM [n5 3], **, p< .01; ***, p< .001). (F): Western blot and (G) its corresponding densitometry, showing
FSTL3 increasing in the protein level in parallel with overexpression of KLF4 but not OCT4. The data presented are representative
or means (6SEM) of three independent experiments. Abbreviations: ECs, endothelial cells; FSTL3, follistatin-like 3; GAPDH, Glyceralde-
hyde 3-phosphate dehydrogenase; GFP, green ﬂuorescent protein; iPS, induced pluripotent stem.
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capillary numbers, when the cells stained with CD144 were
quantiﬁed (Fig. 6F). Importantly, an enhanced engraftment
ability of the (human exogenously delivered) iPS-ECs
overexpressing FSTL3 was clearly demonstrated when double
positive cells for CD144 and mCherry were quantiﬁed (Fig.
6G). There results indicate that iPS-ECs overexpressing FSTL3
Figure 5. FSTL3 regulates endothelial cell (EC) marker expression in induced pluripotent stem (iPS)-ECs by facilitating b-catenin nuclear
translocation through inhibition of GSK3b activity. (A): FSTL3 induced expression of Wnt3, b-catenin, and LEF1 in iPS-ECs, while suppressing
GSK3b expression levels (Data is means6 SEM [n5 3], *, p< .05; **, p< .01; ***, p< .001). (B): Knockdown of FSTL3 in iPS-ECs by short
hairpin RNA(shRNA) signiﬁcantly reduced the expression of b-catenin and LEF1 (Data is means6 SEM [n5 3], *, p< .05; **, p< .01). (C):
Immunoﬂuorescent confocal images showing enhanced b-catenin translocation to the cell nucleus of FSTL3-overexpressing cells compared
to control (EX-mCherry), Scale bar: 50 lm. (D): Luciferase assay showed increased Top Flash promoter activity for cells overexpressing FSTL3
compared to control (EX-mCherry) (Data is means6 SEM [n5 3], **, p< .01). (E): Western blot and its (F) corresponding densitometry,
showing b-catenin knockdown by shRNA. (G): b-catenin was knocked down by shRNA and FSTL3 was overexpressed the following day in
iPS-ECs. Real Time polymerase chain reaction (PCR) data reveal the induction of EC markers and LEF1 mediated by FSTL3 was ablated by b-
catenin knockdown (Data is means6 SEM [n5 3], *, p< .05; ***, p< .001). (H): FSTL3 overexpression in iPS-ECs led to GSK3b decrease
and phospho-GSK3b (pGSK3b) increase in the protein level, as shown by Western blot and its (I) corresponding densitometry. (J): Human
angiogenesis Proteome Proﬁler array analysis revealed the overexpression of FSTL3 leads to induced expression of the angiogenic factor
Endothelin-1 (Data is means6 SEM [n5 3], ***, p< .001). The data presented are representative or means (6SEM) of three independent
experiments. Abbreviations: FSTL3, follistatin-like 3; GSK3b, glycogen synthase kinase-3b; pGSK3b, phospho-GSK3b.
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Figure 6. FSTL3 induced vascular tube formation in vivo and signiﬁcantly improved angiogenesis, neovascularization, and blood ﬂow
recovery in the hind limb ischemic model. Human induced pluripotent stem (iPS)-ECs overexpressing FSTL3 enhanced the formation of
vascular-like tubes in vivo. (A): iPS-ECs overexpressing FSTL3 (EX-FSTL3), signiﬁcantly induced angiogenesis, after subcutaneous injection
in severe combined immunodeﬁciency (SCID) mice, in comparison to the control iPS-ECs (PBS CTL) or control iPS-ECs expressing mCherry
(EX-mCherry), as shown by H&E staining and (B) capillary density quantiﬁcation (Data is means6 SEM [n5 3], **, p< .01). Scale bar: 50
mm. (C): phosphate buffered saline (PBS)-CTL and iPS-ECs overexpressing mCherry (EX-mCherry) or FSTL3 (EX-FSTL3) were injected intra-
muscularly in NOD.CB17-Prkdcscid/NcrCrl SCID mice immediately after induction of hind limb ischemia. Laser Doppler images show
blood ﬂow (BF) in the lower limbs of mice in prone position on day 14. (D): BF recovery in the ischemic foot (calculated as a percentage
ratio between ischemic foot BF and the contralateral foot) for each of the conditions. Statistical analysis shows signiﬁcantly higher BF
recovery in the EX-FSTL3 treated mice at 14 days in comparison to controls; (Data is means6 SEM [n5 3], *, p< .05). (E): Sections of
adductor muscles were stained with CD144 antibody for each condition. (F): Quantiﬁed capillary density of CD144-stained cells,
expressed as capillary number per mm2 (Data is means6 SEM [n5 3], *, p< .05). (G) Quantiﬁed capillary density of CD144- and
mCherry-stained cells (Data is means6 SEM; **, p< .01; quantiﬁcation from 10 random microscopic ﬁelds at 340, scale: 50 lm). The
data presented are representative or means (6SEM) of three independent experiments. Abbreviations: DAPI, 40,6-diamidino-2-phenylin-
dole; ECs, endothelial cells; FSTL3, follistatin-like 3.
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display characteristic endothelial functions when tested in
vivo. In conclusion, our ﬁndings demonstrate that FSTL3 has
the potential to induce vessel formation in vivo, further sup-
porting its important role in improving the function of iPS-
ECs.
FSTL3 Induced EC Differentiation and Tube Formation
in Pre-iPS-ECs Before CD144-Selection
During the early stages of iPS-ECs generation (0–6 days before
CD144 selection), cells overexpressing FSTL3 (EX-FSTL3)
induced EC marker expression in pre-iPS-ECs compared to
control (Ex-mCherry) (Supporting Information Fig. S2A). Fur-
thermore, when equal number of pre-iPS-ECs (40,000 per con-
dition) were seeded on Matrigel (Supporting Information Fig.
S2B) for 8 hours, tube formation was evaluated and quanti-
ﬁed in control (EX-mCherry) versus pre-iPS-ECs overexpressing
FSTL3 (EX-FSTL3) using Image J. The total master segments
length, total segments, total meshes area, and capillary tube
branch points (Supporting Information Fig. S2C–S2F) showed
increased tube formation in the pre-iPS-ECS overexpressing
FSTL3 (Supporting Information Fig. S2C–S2F). These results
demonstrate that FSTL3 has the potential to induce differenti-
ation toward ECs from human iPS cells.
DISCUSSION
Cell reprograming is a highly promising regenerative strategy
to develop novel therapies to improve vascular function in
patients with ischemic diseases. The present study has eluci-
dated, for the ﬁrst time, the remarkable role of FSTL3 in
improving the function and neovascularization potential in
iPS-ECs both in vitro and in vivo. Differentiated ECs typically
demonstrate limited proliferative capacity, as well as increased
instability and senescence [29], which as a result, substantially
compromises their clinical application for treatment of vascu-
lar disease. Understanding key factors to facilitate mainte-
nance of EC generation is important as we move toward cell
therapy, and we have now shown that FSTL3 plays an impor-
tant role in this process.
Follistatins play diverse roles in cell proliferation, wound
healing, and inﬂammation, and this is also true for FSTL3, a
secreted glycoprotein usually associated with cell signaling
and transcription [30], which is important in metabolic events
such as glucose and lipid homeostasis [31] and is also a key
player in regulating hematopoiesis [32]. In addition, FSTL3 is
an established inhibitor of TGF-b family members such as
Activin A and bone morphogenetic proteins [33].
Given the diverse roles of follistatins regarding function
and tissue distribution [10], we sought to determine the role
of FSTL3 in iPS-ECs. In particular, we have investigated the
mechanism by which FSTL3 acts to promote enhancement of
EC markers and function. This particular candidate was chosen
as the only follistatin family member signiﬁcantly highly
expressed in iPS-ECs, which was also the highest expressing
gene compared to other follistatins. Indeed, the ﬁndings of
the present study demonstrate an important role of FSTL3 in
iPS-ECs, and in the early stages of EC differentiation, which
may be signiﬁcant toward our aim of generating therapeuti-
cally relevant ECs for use in both regenerative medicine and
treatment of ischemic diseases.
In this study, using the model of iPS-ECs generation, FSTL3
expression was found to be upregulated by KLF4, a key medi-
ator of EC differentiation [23, 53]. In addition, FSTL3 expres-
sion progressively increased throughout the iPS-ECs
generation process, highlighting a likely angiogenic role. Taken
together, this increase in FSTL3 expression by KLF4 is likely
made possible through the physical interaction of KLF4 with
ElK-1 [34]; with the latter interacting, in turn, with the FSTL3
promoter, as identiﬁed by putative transcription factor binding
site research in the TRANSFAC database [35, 36].
Furthermore, we found that FSTL3 serves an important
regulatory function in iPS-ECs, by increasing expression of EC
markers, a decrease of which is characteristic of EC dysfunc-
tion [37]. This increase in FSTL3 also highlights how important
FSTL3 may be in enhancing iPS-ECs generation and maintain-
ing a more stable EC phenotype. Notably, through further
experiments, we found that the mechanism by which FSTL3
induced the EC marker expression in our system was through
inhibition of GSK3b activity and, therefore, b-catenin translo-
cation to the nucleus. Indeed, in agreement with these ﬁnd-
ings, previous studies have shown that increased EC marker
expression can be linked to suppression of GSK3b by
increased phosphorylation [38], an event followed by b-
catenin translocation from the cytoplasm to the cell nucleus
[39]. Seeking to further elucidate the mechanism behind the
increased GSK3b phosphorylation after FSTL3 overexpression
in our study, angiogenic proﬁler arrays were performed, which
showcased Endothelin-1 as the most highly expressed angio-
genic factor. Endothelin-1 is a peptide known to induce angio-
genic responses in ECs [40] and, most importantly, to increase
Figure 7. Schematic diagram of FSTL3 enhancing iPS-EC function
facilitating b-catenin nuclear translocation through inhibition of
GSK3b activity. FSTL3 is activated by KLF4 during iPS-ECs genera-
tion and holds a pivotal role in enhancing EC marker expression
by enabling b-catenin nuclear translocation through inhibition of
GSK3b activity. This in turn, exerts its own regulatory signaling
effects on enhancing EC function. Abbreviations: EC, endothelial
cell; FSTL3, follistatin-like 3; GSK3b, glycogen synthase kinase-3b;
iPS, induced pluripotent stem.
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phosphorylation of GSK3b, resulting in a substantial inhibition
of GSK3b activity [41, 42], thus, further validating our obser-
vations. Furthermore, b-catenin is a coactivator of the Wnt
family of secreted glycolipoproteins [43] and plays a multi-
functional role in key processes, such as cell cycle regulation
[44], cell to cell adhesion [45], and gene transcription
[46–48]. However, b-catenin signaling is also widely docu-
mented as imperative in the proliferation and survival of ECs
as well as in promoting angiogenesis [49] during both devel-
opment and ischemic disease [50, 51], thereby promoting an
increase in EC markers in iPS-ECs, a fact which is in agree-
ment with our ﬁndings.
Remarkably, when tested in two different in vivo models
of angiogenesis and hind limb ischemia, iPS-ECs overexpress-
ing FSTL3 were able to induce increased angiogenesis. This
was indicated by enhanced capillary formation, greatly
improved blood ﬂow recovery as well as by increases in the
EC-speciﬁc marker (CD144) expression, indicating a key role of
FSTL3 in promoting angiogenesis and neovascularization.
These results demonstrate the importance of FSTL3-expressing
iPS-ECs used in in vivo models, exhibiting increased function-
ality potential. In further agreement with this study, previous
research focusing on other follistatins and FSTL proteins has
provided supporting evidence that they may play a direct or
indirect role in regulating EC function and increasing angio-
genesis. For example, follistatin has been reported to promote
angiogenesis in the rabbit cornea [17] and also be upregu-
lated in human umbilical vein endothelial cells in response to
VEGF, a central migratory, sprouting, and proliferation growth
factor [52].
CONCLUSION
Our data clearly demonstrates that FSTL3, which is regulated
by KLF4, plays an important role in enhancing EC function of
iPS-ECs. Our observations suggest that FSTL3 facilitates
b-catenin nuclear translocation by inhibition of GSK3b activity
through Endothelin-1, enhancing, in turn, b-catenin’s signaling
effects on increasing EC marker expression. The schematic dia-
gram of this proposed mechanism is shown in Figure 7. This
novel strategy for improving EC generation based on deﬁned
mechanisms could therefore shed further light on the process.
In addition, it can have an enormous impact on efﬁciency and
production of therapeutically relevant numbers of cells. The
generated ECs could eventually be used for patient-speciﬁc
therapy, particularly toward treatment of vascular diseases
where EC dysfunction plays a central role.
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